Skip to content
Kalpvruksh Markets
Offline Log in

MANIPALHOSNSEOffline

Manipal Health Enter · INE459N01021
657.25−9.95 (−1.49%)last close · 05 Nov 2026
Prev close
667.20
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
—

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20-day average · below its 50-day average
  • +0.7% vs Nifty 500
  • traded value 1.0× usual · delivery 62% vs 51% usual
  • MF schemes in Sept 2026: 6 bought, 24 cut · promoter pledge 8.5%
  • msci standard: close to add (2026-11) · msci small: close to add (2026-11) · ftse large_mid: add candidate (2027-03)

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.8×
median 5,82,560
Delivered
4,69,874
Of volume
50%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+2.9%−2.8 pts—
1 month−4.8%−9.0 pts—
3 months−1.5%+0.7 pts—
6 months———
1 year———

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+1.2%
above
vs 50-day average
−6.0%
below
vs 200-day average
—
not enough history
ATR (14)
4.1%
typical daily range
Volatility
41%
1 month, annualised
Beta
—
vs Nifty 500, 1 year
Traded value
1.0×
vs usual
Delivery
62%
usual 51%
From the 52-week high
—
place in range 0% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupMar 22Sep 26
Promoters44.9%72.1%
FPI0.0%3.5%
Mutual funds0.0%4.6%
Other DII0.0%2.3%
Individuals0.0%1.1%
Others55.1%16.4%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
8.5%
Of all shares
6.1%
Mar 22 0.0%Sep 26 8.5%

Holders

Sep 26

All shareholders
1,72,129
Individuals
1,66,381

Which funds bought and sold

No fund holds this companyNo Indian mutual fund disclosed a position at the last quarter end.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 266624240−3.3%₹3,725 cr
Aug 2664281605+160.1%₹4,146 cr
Jul 264141000—₹1,233 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Takeover (SAST)
    Manipal Health Enterprises Limited has informed the Exchange that
    02 Nov 2026
  • Takeover (SAST)
    Manipal Health Enterprises Limited has informed the Exchange about disclosure under SEBI Takeover Regulations
    30 Oct 2026
  • Takeover (SAST)
    Dr. Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd, Cypress Holdings, Manipal Research & Management Services International, MEMG International India Private Limited, Manipal Education and Medical Group India Private Limited has Submitted to the Exchange a copy of Disclosur
    04 Sept 2026
  • Board outcome
    Manipal Health Enterprises Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    21 Aug 2026
  • Block deal: SELL
    18,97,973 at ₹630 — PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITED
    21 Oct 2026
  • Block deal: BUY
    18,97,973 at ₹630 — PI OPPORTUNITIES AIF V LLP
    21 Oct 2026

MANIPALHOS: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.